Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
Blood Cancer
DiseaseRelated News
CAR-T Therapy Expands Beyond Cancer: Ireland Milestone, New Trials and Genetic Insights
CAR-T therapy reaches 150 patients in Ireland and expands into autoimmune trials for lupus and MS. Kyverna's miv-cel nears FDA approval for stiff person syndrome, and new research links gene variants to CAR-T outcomes.
AstraZeneca Deepens China Push With COPD Drug License, Lung Cancer Deal and $15bn Investment
AstraZeneca is expanding in China with a $200m upfront COPD drug license from Sino Biopharmaceutical, a $1.5bn licensing deal for Dizal's Zegfrovy, and a $15bn manufacturing and R&D investment. The deals add revenue-generating assets to its respiratory and oncology portfolios.
Digital Symptom Monitoring and Survivorship Research Boost Cancer Patient Wellbeing
A clinical trial showed that digital symptom check-ins improved quality of life for advanced cancer patients, especially underserved groups. Researchers are also advancing survivorship care and investigating ageing biology to improve recovery in older patients.
New therapies and testing advances reshape multiple myeloma care
New therapies including CAR-T, bispecific antibodies and dual-antibody immunotherapy are reshaping multiple myeloma care. Advances in genomic testing may also improve risk assessment and treatment decisions.
Global antibody drug conjugate market seen reaching $32.66 billion by 2035
The global antibody drug conjugate market is calculated at USD 14.76 billion in 2026 and is expected to reach USD 32.66 billion by 2035. North America held a 53% share in 2025, while Asia Pacific is projected to grow fastest.
Calls grow to bring CAR-T cell therapy into New Zealand’s public health system
Calls are growing to bring CAR-T cell therapy to New Zealand as the current trial is set to end later this year. There is no clear path to public availability.
Blood Cancer Healing Center adds research labs and wellness suite
The University of Cincinnati Cancer Center’s Blood Cancer Healing Center added research laboratories and the UC Osher Wellness Suite and Learning Kitchen. The expansion joins clinical services launched in July 2024 and adds new research, wellness and community programming space.
LigaChem Accelerates ADC Pipeline Amid Losses, Lonza Expands Bioconjugate Capabilities
LigaChem Biosciences is expanding R&D investment in its ADC pipeline despite widening losses, with major clinical milestones expected this year. Concurrently, Lonza has enhanced its advanced synthesis capabilities for ADC development, including dual-payload technology and expanded Netherlands facility infrastructure.
High-Resolution Imaging Reveals HTLV Virus Structure for Potential Cancer Treatment
Researchers used cryo-EM/ET imaging to analyze the HTLV capsid protein structure, revealing insights into virus assembly and potential therapeutic targets for adult T-cell leukemia/lymphoma. The study identified how the virus is assembled and reproduced, with findings that could inform drug design similar to HIV treatments. This research addresses a critical need as there are currently no approved therapeutics for HTLV infection.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07714044 |
Rutgers University Study of the Genetics of Blood Cancers |
NOT_YET_RECRUITING | |
| NCT07305090 |
Development of a Multi-biomarker Panel for Prognostic Stratification and Treatment Response Prediction in Acute Graft Versus Host Disease of the Gut |
RECRUITING | |
| NCT07148180 |
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax |
RECRUITING | PHASE1/PHASE2 |
| NCT07052916 |
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties |
RECRUITING | NA |
| NCT06904066 |
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies |
RECRUITING | PHASE1 |
| NCT06817759 |
Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer |
NOT_YET_RECRUITING | NA |
| NCT06645132 |
Understanding the Implementation of Cued Exercise Using Wearable Devices and a Custom Smartphone Application Following Bone Marrow Transplant. |
ACTIVE_NOT_RECRUITING | NA |
| NCT06582849 |
Enhanced Assistance During Radiotherapy for Unmet Essential Needs |
COMPLETED | NA |
| NCT06574308 |
Clinical Evaluation of the Scopio Cell Morphology Technology |
NOT_YET_RECRUITING | |
| NCT06543511 |
MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies |
WITHDRAWN | NA |